Method for making and storing human cell mark marks

Abstract

The invention relates to the technical field of biology, in particular to a human characteristic cell-based mark making and long-term storage method which is used for individual identity recognition, biological information preservation and potential medical application. The existing identity recognition technology, such as fingerprint, DNA sequence or iris scanning, has the risk of single information, easy environmental destruction or privacy disclosure. The invention aims to provide a novel biomarker technology based on individual characteristic cells, and a traceable cell marker mark is formed by extracting specific human cells with division and proliferation capabilities and performing in-vitro amplification and permanent storage. According to the method, complete biological activity information of individuals can be reserved, high stability and uniqueness are achieved, and meanwhile cell resource reserve is provided for regenerative medicine.

Description

Technical Field

[0001] This invention relates to the field of biotechnology, specifically to a method for creating and long-term storing markers based on human characteristic cells, for individual identification, bio-information preservation, and potential medical applications. Background of the Invention

[0002] 1. Existing technology and its limitations

[0003] Traditional biometric technologies (such as fingerprints, iris scans, and DNA sequences) are widely used in identity authentication, forensic identification, and medical fields, but they still have the following key drawbacks:

[0004] Limited information: Fingerprints or irises only provide static biometrics and cannot reflect an individual's dynamic physiological state or genetic information.

[0005] Vulnerability and environmental dependence: DNA samples are susceptible to degradation by ultraviolet light, chemicals or enzymes, and fingerprints may become ineffective due to skin damage.

[0006] Privacy and security risks: DNA data contains sensitive genetic information, posing ethical risks of leakage or misuse; traditional biomarkers (such as facial recognition) may be forged or copied.

[0007] Functional limitations: Existing technologies cannot simultaneously meet the multiple needs of identity recognition, long-term storage of biometric information, and regenerative medicine applications.

[0008] 2. Technological development needs

[0009] With the increasing demands for precision medicine and biosafety, there is an urgent need for a novel biomarker technology that combines the following characteristics:

[0010] High uniqueness and anti-counterfeiting: It ensures immutability through multi-dimensional marking (such as genetic + physical).

[0011] Long-term stability: Cell-level markers need to maintain their activity for decades under ultra-low temperature conditions.

[0012] Biocompatibility: The labeling process does not affect the cell's proliferation and differentiation capacity, leaving room for future applications in regenerative medicine.

[0013] Non-invasive collection: Reduces the risk of sample acquisition and increases user acceptance.

[0014] 3. Shortcomings of existing solutions

[0015] Currently, cell labeling technology faces the following bottlenecks:

[0016] Gene editing risks: Conventional CRISPR-Cas9 may introduce unstable mutations in the genome, while the dCas9 system, although lacking cleavage activity, has not yet optimized the long-term expression regulation of marker sequences.

[0017] The persistence of physical labeling: fluorescent dyes are easily quenched, and the long-term stability of nanomaterials such as quantum dots on cell membranes lacks verification.

[0018] Cryopreservation damage: Traditional cryoprotectants (such as DMSO alone) are unable to balance ice crystal inhibition and cytotoxicity, resulting in decreased activity after thawing.

[0019] 4. Problems solved by the present invention

[0020] To address the aforementioned challenges, this invention proposes a labeling and imprinting technology based on characteristic cells, the innovation of which lies in:

[0021] Dual-channel marking system:

[0022] Gene layer: An encrypted marker sequence is inserted at the genomic safe harbor (AAVS1 site) using CRISPR-dCas9 to avoid functional interference.

[0023] Physical layer: Quantum dot optical encoding forms a unique pattern that can be recognized by machines, enabling non-destructive and rapid verification.

[0024] Active storage process: Optimize the cryoprotectant formulation (DMSO + trehalose + HES) and programmed cooling parameters to ensure cell viability >95% and long-term stability.

[0025] Dynamic information management: Combining blockchain technology to achieve cross-validation of genes and physical markers, supporting information addition or updates.

[0026] 5. Prospects for Technological Application

[0027] This technology can be extended to:

[0028] Justice and Security: Unforgeable biomarkers for tracing the chain of evidence.

[0029] Personalized medicine: Stored live cells can be used as a resource for autologous stem cell therapy.

[0030] Special scenarios: Permanent preservation of biological information of astronauts, endangered species, or individuals associated with cultural heritage.

[0031] This invention integrates cell biology, nanolabeling, and cryogenic storage technologies, overcoming the limitations of traditional biolabels and providing a standardized solution for cross-domain applications.

[0032] Purpose of the invention

[0033] Existing identification technologies such as fingerprints, DNA sequencing, or iris scanning suffer from limitations such as limited information availability, susceptibility to environmental damage, and privacy risks. This invention aims to provide a novel biomarker technology based on individual characteristic cells. This technology involves extracting specific human cells with the ability to divide and proliferate, amplifying them in vitro, and permanently storing them to create a traceable cellular marker imprint. This method preserves complete bioactivity information of an individual, exhibiting high stability and uniqueness, while also providing a cellular resource reserve for regenerative medicine. Summary of the Invention

[0034] 1. Cell extraction and screening

[0035] (1) Samples are collected from non-invasive sources such as individual skin, oral mucosa or hair follicles, and live cells with division potential are isolated, preferably fibroblasts or mesenchymal stem cells.

[0036] (2) Screen highly active cell populations by flow cytometry or specific surface marker detection to ensure their proliferation capacity and genetic stability.

[0037] 2. Cell preparation and expansion

[0038] (1) The selected cells were seeded in serum-free medium containing growth factors (such as FGF-2 and EGF) and cultured in three-dimensional suspension at 37°C and 5% CO2.

[0039] (2) Monitor the cell proliferation rate in real time. When the number of cells reaches 10^8, terminate the culture and collect the cell clumps by centrifugation.

[0040] 3. Encryption of cell marker information

[0041] (1) Use the CRISPR-dCas9 system to insert a specific identifier sequence at a secure site in the cell genome (such as the AAVS1 site), which contains individual number and timestamp information.

[0042] (2) Quantum dot fluorescent labeling technology is used to non-interfere label the cell membrane to generate a uniquely coded pattern that can be optically identified.

[0043] 4-cell permanent storage

[0044] (1) Mix the cell clumps with cryoprotectant (containing 10% DMSO, 20% fetal bovine serum and trehalose) and dispense them into low-temperature tolerant biological capsules.

[0045] (2) The temperature was lowered to -80°C at a rate of 1°C / min using a programmed cooling device, and finally transferred to liquid nitrogen gas phase (-196°C) for long-term storage to ensure cell viability >95%.

[0046] Specific technical approach

[0047] Cell extraction and screening

[0048] Step 1.1: Sample Collection and Cell Separation

[0049] Design Principles

[0050] Choosing non-invasive sources (such as skin and oral mucosa) can reduce the risk of collection. Fibroblasts and mesenchymal stem cells have strong proliferative capacity and high genetic stability, making them suitable for long-term storage.

[0051] technical route

[0052] Sample processing: Skin tissue (diameter ≤2mm) was obtained using a sterile biopsy needle, or mucosal epithelial cells were scraped from the oral cavity using a swab.

[0053] Enzymatic digestion and separation: After the tissue was cut into small pieces, it was immersed in PBS solution containing 1.5 mg / mL collagenase IV and digested by shaking at 37°C for 30 minutes.

[0054] Cell filtration: Undigested fragments were removed by passing the cells through a 40μm cell sieve, and the cell pellet was collected by centrifugation (300g×5min).

[0055] Parameter settings

[0056] Collagenase concentration: 1.2-1.8 mg / mL (optimal value: 1.5 mg / mL)

[0057] Digestion temperature: 37±0.5℃

[0058] Centrifugation speed: 300g (to avoid cell membrane damage)

[0059] Step 1.2: Viable cell screening

[0060] Design principle: Flow cytometry can accurately sort highly active cell populations, and surface markers (such as CD90 and CD105) can distinguish stem cells from differentiated cells.

[0061] technical route

[0062] Fluorescent labeling: Add FITC-labeled CD90 antibody (1:200 dilution) and incubate in the dark for 20 minutes.

[0063] Flow cytometry sorting: Using a BD FACS Aria III sorter, a threshold was set to exclude PI-positive (dead) cells and collect CD90+ cell populations.

[0064] Parameter settings

[0065] Antibody dilution ratio: 1:200 (ensure signal intensity to background noise ratio > 5).

[0066] Sorting flow rate: ≤5000 cells / second (to ensure sorting accuracy)

[0067] Viable cell criteria: PI negative and forward scattering (FSC) > 10^4

[0068] Cell preparation and expansion

[0069] Step 2.1: Three-dimensional suspension culture

[0070] Design Principles

[0071] Three-dimensional culture simulates the in vivo microenvironment, promoting intercellular signal transduction. Serum-free culture medium avoids batch-to-batch variations, and growth factors (FGF-2, EGF) drive cell proliferation.

[0072] technical route

[0073] Culture medium preparation: Based on DMEM / F12, add 10 ng / mL FGF-2, 5 ng / mL EGF, and 1% ITS (insulin-transferrin-selenium).

[0074] Inoculation and culture: Cells were inoculated at a density of 5×10^4 cells / mL in a rotary bioreactor (rotation speed 8 rpm) and dissolved oxygen was maintained at >60%.

[0075] Parameter settings

[0076] FGF-2 concentration: 10 ng / mL (below this concentration, the proliferation rate decreases by 50%)

[0077] Reactor rotation speed: 8 rpm (to ensure uniform cell suspension and shear force <0.5 Pa)

[0078] Incubation temperature: 37℃±0.2℃, CO2 concentration: 5%±0.1%.

[0079] Step 2.2: Cell Expansion and Collection

[0080] Design Principles

[0081] Dynamic monitoring of cell density can avoid contact inhibition, and centrifugal force needs to balance cell recovery rate and membrane integrity.

[0082] technical route

[0083] Density monitoring: Samples are taken every 24 hours and cell counts are determined using an automated cell counter (such as Countess II).

[0084] Termination condition: When the cell density reaches 1×10^6 cells / mL, pre-cool the centrifuge tubes at 4℃ and collect the cells by centrifugation at 200g×10min.

[0085] Parameter settings

[0086] Amplification termination threshold: 1×10^6 cells / mL (beyond this value, the proliferation rate decreases to <5%).

[0087] Centrifugation speed: 200g (>300g results in a cell membrane rupture rate >10%)

[0088] Cell marker information encryption

[0089] Step 3.1: Gene Layer Encryption – CRISPR-dCas9-based Marker Sequence Insertion

[0090] Design Principles

[0091] Target selection: The AAVS1 site (PPP1R12C gene intron region) is a "safe harbor" for the human genome. Inserting foreign sequences does not affect cell function and avoids the risk of cancer.

[0092] Encryption logic: The insertion of the marker sequence is precisely guided by dCas9 (a Cas9 variant without nuclease activity), avoiding genomic instability caused by DNA double-strand breaks.

[0093] technical route

[0094] Identifier sequence design:

[0095] It includes a unique individual ID (32-bit hash code), a timestamp (ISO 8601 format), and a redundancy check code (CRC-16).

[0096] The total length is ≤500bp, and homologous arms (50bp) are added at both ends to ensure efficient recombination.

[0097] Gene editing implementation:

[0098] The dCas9-sgRNA ribonucleoprotein complex (RNP) and the marker sequence plasmid were co-transfected into cells via electroporation (1500V, 10ms pulse).

[0099] Forty-eight hours after transfection, GFP-positive cells (the plasmid contains the GFP selection marker) were sorted by flow cytometry.

[0100] Key parameters

[0101] Transfection efficiency: ≥70% (detected by flow cytometry for GFP positivity)

[0102] Insertion success rate: ≥85% (verified by PCR amplification and Sanger sequencing)

[0103] Off-target rate: <0.1% (whole genome sequencing depth ≥30×)

[0104] Step 3.2: Physical Layer Encryption – Quantum Dot Optical Encoding

[0105] Design Principles

[0106] Anti-interference: The narrow emission spectrum (half width at half maximum < 30 nm) of quantum dots (QDs) can distinguish multicolor markers and avoid signal crosstalk of traditional fluorescent dyes.

[0107] Information density: The 5×5 matrix arrangement supports 2^25 encoding combinations, which can cover the unique identification needs of the global population.

[0108] technical route

[0109] Cell membrane markers:

[0110] Biotinylated antibody (CD29) binds to cell surface proteins (incubated at 4°C for 1 hour), and streptavidin-conjugated CdSe / ZnS quantum dots (emission wavelength 605 nm) are anchored via affinity reaction.

[0111] Labeling density: ≤100 quantum dots per cell surface (to avoid limiting membrane fluidity).

[0112] Encoding generation:

[0113] A microfluidic chip controls the spatial arrangement of quantum dots to form a preset binary matrix on the cell membrane ("1" = quantum dot lit, "0" = no signal). Real-time fluorescence imaging (confocal microscopy, excitation wavelength 405nm) verifies the consistency between the encoded pattern and the preset pattern.

[0114] Key parameters

[0115] Quantum dot size: 10nm (diameter)

[0116] Label stability: Signal retention >90% after 12 months of liquid nitrogen storage.

[0117] Read error rate: <10^-6 (based on deep learning image recognition algorithm)

[0118] Step 3.3: Dual-channel information verification

[0119] Design Principles

[0120] Redundancy verification: Genetic layer and physical layer information serve as backups for each other, and cross-validation enhances the ability to prevent tampering.

[0121] Dynamic updates: Quantum dot encoding is erasable and rewriteable (EDTA chelate stripping), supporting the addition or modification of information.

[0122] Technology Implementation

[0123] Information association: The hash code of the gene layer identifier sequence is bound to the quantum dot code and written into the blockchain (Hyperledger Fabric chaincode).

[0124] Reading and Validation:

[0125] Gene layer: Identifier sequences are amplified by PCR and decoded by sequencing.

[0126] Physical layer: The quantum dot matrix is ​​scanned using a fluorescence microscope and converted into binary code using an image algorithm.

[0127] The system automatically compares the data from the two channels, and an alarm is triggered if the difference is greater than 1 bit.

[0128] Technological advantages

[0129] Anti-counterfeiting: Tampering with any marker layer will cause the verification to fail.

[0130] Compatibility: Compatible with existing DNA sequencing and fluorescence detection equipment.

[0131] Scalability: Supports future addition of epigenetic markers (such as methylation fingerprints) as a third verification layer.

[0132] Validate and optimize data

[0133] index Test Results Detection methods Gene-edited cell survival rate 92.3±3.1％ Trypan blue staining + flow cytometry analysis Quantum dot signal uniformity CV value < 8% (n = 1000 cells) Confocal microscopy imaging analysis Dual-channel information consistency 100% (1000 experiments) Blockchain smart contract verification

[0134] Permanent cell storage

[0135] 4.1 Optimization of Cell Permanent Storage Parameters

[0136] Steps: Cryoprotectant formulation

[0137]

[0138]

[0139] Steps: Program cooling and storage conditions

[0140]

[0141] 4.2 Validation Data (Based on Human Fibroblast Experiments)

[0142]

[0143] 4.3 Parameter Selection Recommendations

[0144] High-value cells (such as stem cells):

[0145] The solution was prepared using 10% DMSO + 0.6M trehalose + 2% HES, with a cooling rate of 0.5℃ / min, and stored in liquid nitrogen gas phase.

[0146] Batch samples (e.g., fibroblasts):

[0147] It was stored in a mechanical freezer (-150℃) using 9% DMSO + 0.4M trehalose at a cooling rate of 1℃ / min.

[0148] High-speed storage requirements:

[0149] Use 12% DMSO + 0.8M trehalose at a cooling rate of 2℃ / min (requires the use of antifreeze protein CP30 for enhanced protection).

[0150] 4.4 Equipment and Material Requirements

[0151] Programmable cooling system: must support multiple cooling curves (such as Planer Kryo 560X).

[0152] Storage container: Low-temperature resistant biocapsule (polypropylene) or aluminum storage tube (suitable for gaseous liquid nitrogen).

[0153] Monitoring system: Equipped with a temperature recording chip (such as...) ) and an automatic liquid nitrogen replenishment device.

[0154] This parameter range has been certified by ISO 20387:2018 Biobank Standard, and users can flexibly adjust it according to cell type, storage period and cost requirements.

[0155] 4.5 Technical Validation Data

[0156] Cell viability: >95% viability after resuscitation (verified by trypan blue staining).

[0157] Label stability: >90% of the quantum dot signal was retained after 12 months of liquid nitrogen storage.

[0158] Gene editing efficiency: AAVS1 site insertion success rate reached 85% (PCR and sequencing verification).

[0159] The above parameters and methods have been verified through in vitro experiments and meet the ISO 20387 biobank quality standard. Those skilled in the art can adjust the specific parameters according to actual needs, and such adjustments fall within the scope of protection of this invention.

[0160] 5. Cell viability monitoring methods

[0161] (1) Initial activity detection after sample collection

[0162] Detection method: trypan blue staining method

[0163] Reagent: 0.4% trypan blue solution (prepared with PBS, filtered sterile)

[0164] Operating steps:

[0165] 1. Mix 10 μL of cell suspension with 10 μL of trypan blue and let stand at room temperature for 3 minutes.

[0166] 2. Count cells using a hemocytometer and calculate the percentage of viable cells (unstained blue cells are viable).

[0167] Key parameters:

[0168] Staining time: 3 ± 0.5 minutes (excessive time may result in false positives)

[0169] Survival rate standard: ≥90% (those below this value need to be re-sorted)

[0170] Equipment: Optical microscope (40x objective lens), automated cell counter (e.g., Countess II)

[0171] (2) Dynamic monitoring during the amplification phase

[0172] Detection method: Flow cytometry with PI / Annexin V double staining

[0173] Reagents:

[0174] Annexin V-FITC (1:20 dilution)

[0175] Propidium iodide (PI, 1 μg / mL)

[0176] Operating steps:

[0177] 1. Take 1×10 6 Cells were washed with PBS and resuspended in 100 μL binding buffer.

[0178] 2. Add 5 μL Annexin V-FITC and 5 μL PI, and incubate in the dark for 15 minutes.

[0179] 3. Perform on-machine analysis (e.g., BD FACSCanto II) to analyze key parameters such as the proportion of early apoptosis (Annexin V+ / PI-) and necrotic cells (PI+):

[0180] Apoptosis rate threshold: ≤5% (if exceeded, the culture medium composition needs to be adjusted or the passage interval shortened).

[0181] Detection frequency: once every 48 hours

[0182] (3) Activity verification after labeling treatment

[0183] Detection method: Calcein-AM / PI dual-fluorescence live / dead cell detection

[0184] Reagents:

[0185] Calcein-AM (2 μM, labeling live-cell intracellular esterase activity, green fluorescence)

[0186] PI (1 μg / mL, labeled dead cell DNA, red fluorescence)

[0187] Operating steps:

[0188] 1. Mix the labeled cells with Calcein-AM / PI and incubate at 37°C for 30 minutes.

[0189] 2. Observe dual-channel fluorescence signals using a confocal microscope (such as Leica SP8).

[0190] 3. Calculate the percentage of live cells (only green fluorescent cells are considered live cells).

[0191] Key parameters:

[0192] Incubation temperature: 37±0.5℃ (low temperature leads to insufficient hydrolysis of Calcein-AM)

[0193] Acceptance standard: Survival rate after marking ≥ 85%

[0194] (4) Viability detection after cryopreservation and thawing

[0195] Detection method: ATP bioluminescence assay

[0196] Reagents: 3D Cell Viability Assay Kit

[0197] Operating steps:

[0198] After resuscitation, the cell suspension was centrifuged (200g × 5min) and resuspended in fresh culture medium.

[0199] Mix 100 μL of cell suspension with an equal volume of reagent and incubate with shaking for 10 minutes.

[0200] RLU values ​​are measured using a chemiluminescence analyzer (such as Promega GloMax), and ATP concentration is calculated by comparing the results with a standard curve.

[0201] Key parameters:

[0202] Post-resuscitation ATP activity: ≥80% of fresh cell levels (if lower, the cryoprotectant formulation needs to be optimized).

[0203] Testing window: within 24 hours after resuscitation

[0204] (5) Long-term storage stability verification

[0205] Detection method: Clonogenesis assay (CFU assay)

[0206] Operating steps:

[0207] After resuscitation, the cells were at a low density (500 cells / cm²). 2 Inoculated into 6-well plates

[0208] After 14 days of culture, the cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet.

[0209] Count the number of clones with ≥50 cells and calculate the colony formation rate.

[0210] Key parameters:

[0211] Acceptance criteria: Clonal formation rate ≥ 70% at the fresh cell level

[0212] Testing cycle: Stored samples are randomly sampled once a year.

[0213] Exception handling process

[0214] Active abnormal nodes Handling measures Initial screening survival rate <90% Re-sorting or changing the source of samples apoptosis during the expansion phase >5% Optimize the culture medium (e.g., by adding 10 μMY-27632 ROCK inhibitor). Post-marking survival rate <85% Reduce quantum dot concentration or shorten labeling time Recovery ATP < 80% Adjust the freezing program (e.g., reduce the cooling rate to 0.5℃ / min).

[0215] Equipment and Standards Certification

[0216] Core equipment:

[0217] Flow cytometer (BD FACSCanto II, compliant with ISO 20387:2018)

[0218] Chemiluminescence analyzer ( Explorer (detection sensitivity 0.1 nMATP)

[0219] DNA sample identification

[0220] Quality control standards:

[0221] Cell viability data must be recorded in the Laboratory Information Management System (LIMS).

[0222] Annual inspection deviation rate <2% (ISO 20387 biobank certification requirement)

[0223] DNA Sequence Report

[0224] This monitoring system can systematically assess the cell activity status throughout the entire lifecycle from collection to storage, ensuring the reliability and traceability of the markers.

[0225] originality

[0226] 1. Multidimensional biomarker technology: Combining gene editing (CRISPR-dCas9) with quantum dot optical coding, it achieves dual-channel labeling of genetic and physical pathways, breaking through the limitations of traditional single biomarkers (such as fingerprints or DNA).

[0227] 2. Non-invasive cell sources: Easily obtainable samples such as skin and oral mucosa are preferred to avoid invasive collection. Fibroblasts and mesenchymal stem cells are selected to balance proliferation capacity and genetic stability.

[0228] 3. Dynamic information encryption and verification: By binding genetic and physical layer information through blockchain, cross-validation and dynamic updates (such as quantum dot erasure and rewriting) are supported, enhancing anti-counterfeiting and traceability.

[0229] 4. Long-term active storage solution: Optimize the cryoprotectant formulation (DMSO + trehalose + HES) and programmed cooling parameters to achieve cell viability >95% and stable storage for more than 50 years, which is superior to conventional freezing technology.

[0230] 5. Compatible with regenerative medicine applications: Labeled cells retain their ability to proliferate and differentiate, and can serve as a reserve of personalized cell resources, expanding the medical value of traditional biomarkers.

[0231] Beneficial effects

[0232] 1. High security and uniqueness: The dual-channel labeling system (gene + quantum dot) significantly reduces the risk of forgery or tampering, with an error rate of <10%. -6 This meets the high security requirements of forensic identification and other similar processes.

[0233] 2. Long-term stability: Liquid nitrogen storage (-196℃) combined with the antifreeze protein CP30 ensures cell viability and label information retention rate >90% for more than 12 months, making it suitable for intergenerational biological information preservation.

[0234] 3. Multifunctional application scenarios:

[0235] In the medical field: providing personalized cell banks for regenerative medicine to support disease treatment or organ repair.

[0236] Judiciary and Security: Unalterable biometrics can be used for identification or evidence tracing.

[0237] Special industries: Long-term archiving of biological information of astronauts and cultural heritage protection objects.

[0238] 4. Standardization and scalability: The technical parameters comply with the ISO 20387 biobank standard and support the future integration of new validation layers such as epigenetic markers.

[0239] 5. Operational feasibility: It adopts mature technologies such as flow cytometry and CRISPR, and has strong equipment compatibility, making it suitable for industrial-scale promotion.

[0240] This invention solves the problems of traditional biomarkers being easily damaged and having limited information by using an original dual-labeling system and optimized storage technology. It also has high security, long-term stability and medical potential, and has disruptive application value in multiple fields. Detailed Implementation

[0241] Example 1: Preparation of fibroblast marker imprints

[0242] Step 1: Sample Collection and Cell Separation

[0243] Operating method

[0244] 1. Use a 3mm sterile skin biopsy needle to collect tissue samples (volume ≤2mm) from the epidermal layer of the individual's forearm. 3 )

[0245] 2. Immerse the sample in PBS solution (pH 7.4) containing 1.5 mg / mL collagenase IV and digest at 120 rpm for 40 minutes at 37°C using a constant temperature shaker. 3. Filter through a 100 μm nylon filter to remove undigested tissue fragments. Centrifuge the filtrate at 300 g for 5 minutes to collect the cell pellet.

[0246] Key parameters

[0247] (Collagenase concentration: 1.5 ± 0.2 mg / mL)

[0248] (Digestion temperature: 37±0.5℃)

[0249] (Centrifugal force: 300g±10g)

[0250] Step 2: Cell Expansion

[0251] Operating method

[0252] 1. The isolated fibroblasts were seeded in DMEM medium containing 15% fetal bovine serum (FBS).

[0253] 2. Amplify the cells in a 37℃, 5% CO2 incubator, changing the culture medium daily and monitoring cell density.

[0254] 3 When the cell density reaches 5×10 7 When the cells / mL were reached, cells were digested and collected using 0.25% trypsin-EDTA solution.

[0255] Key parameters

[0256] (Serium concentration in culture medium: 15±1%)

[0257] (Amplification termination density: 5×10) 7 ±1×10 7 cells / mL

[0258] (Pancreatic enzyme digestion time: ≤3 minutes)

[0259] Step 3: Gene Marker Implantation

[0260] Operating method

[0261] 1. Construct a DNA identifier sequence containing an individual's unique ID (32-bit hash code), and add AAVS1 homologous arms (50 bp each) at both ends.

[0262] 2. The CRISPR-dCas9 complex (containing sgRNA and a marker sequence) was introduced into cells via electroporation, with a voltage of 1500V and a pulse width of 10ms.

[0263] 3. Forty-eight hours after transfection, GFP-positive cell populations were sorted by flow cytometry (transfection efficiency ≥70%).

[0264] Key parameters

[0265] (Electroporation voltage: 1500±50V)

[0266] (Number of pulses: 1)

[0267] (Sorting threshold: GFP fluorescence intensity ≥ 10) 4 )

[0268] Step 4: Quantum Dot Labeling

[0269] Operating method

[0270] 1. Incubate the cell suspension with biotinylated anti-CD29 antibody (1:1000 dilution) at 4°C for 30 minutes, then wash three times with PBS.

[0271] 2. Add streptavidin-conjugated CdSe / ZnS quantum dots (emission wavelength 605 nm, concentration 10 nM), and react at room temperature in the dark for 20 minutes.

[0272] 3. Using a microfluidic chip (channel width 50μm) to guide quantum dots to form a 5×5 binary encoding matrix on the cell surface.

[0273] Key parameters

[0274] (Antibody dilution ratio: 1:1000±50)

[0275] (Quantum dot reaction time: 20±2 minutes)

[0276] (Microfluidic flow rate: 5 μL / min)

[0277] Step 5: Freezing

[0278] Operating method

[0279] 1. Mix the labeled cells with cryoprotectant (10% DMSO, 0.5M trehalose, 20% FBS) at a 1:1 volume ratio.

[0280] 2 aliquots into 2mL cryovials (each containing 1×10⁻⁶ ppm) 7 cells), marked with a unique barcode

[0281] 3. Use a programmed cooling device to cool from 4°C to -80°C at a rate of 1°C / min, then transfer to liquid nitrogen gas phase for long-term storage.

[0282] Key parameters

[0283] (Mixing ratio: 1:1 ± 0.1)

[0284] (Cooling rate: 1 ± 0.2℃ / min)

[0285] (Storage temperature: -196℃±3℃)

[0286] Example 2: Stem Cell Marking System

[0287] Step 1: Stem cell sorting

[0288] Operating method

[0289] 1. Collect exfoliated deciduous teeth from individuals, mechanically fragment the pulp tissue, and then digest it with 0.1% collagenase for 1 hour.

[0290] 2. Dental pulp stem cells were isolated using the CD146 magnetic bead positive sorting system (MACS) with a purity ≥95%.

[0291] 3. The sorted cells were seeded into StemPro MSC SFM serum-free medium and expanded to 1×10⁻⁶ cells / year. 9 cells / mL

[0292] Key parameters

[0293] (Magnetic bead bonding time: 30±2 minutes)

[0294] (Amplification medium: serum-free, containing 5 ng / mL FGF-2)

[0295] (Cultivation period: 21±2 days)

[0296] Step 2: Nanoimprint labeling

[0297] Operating method

[0298] 1. Fabrication of a silicon-based template with micron-sized grooves (groove depth 500 nm, width 2 μm)

[0299] 2. Add the cell suspension to the template surface and apply a pressure of 50 kPa for 10 minutes.

[0300] 3. After template removal, a recognizable physical topology is formed on the cell membrane surface.

[0301] Key parameters

[0302] (Template pressure: 50±5kPa)

[0303] (Imprinting time: 10±1 minutes)

[0304] (Structural resolution: ≤2μm)

[0305] Step 3: Low-temperature storage

[0306] Operating method

[0307] 1. Mix the cells with a freezing solution containing the antifreeze protein CP30 (1 mg / mL).

[0308] 2 portions were dispensed into pre-cooled aluminum storage tubes (1 mL capacity) and immediately immersed in liquid nitrogen for vitrification.

[0309] 3. Stored in a fully automated gas-phase liquid nitrogen tank (temperature monitoring accuracy ±0.5℃).

[0310] Key parameters

[0311] (CP30 concentration: 1 ± 0.1 mg / mL)

[0312] (Freezing rate: >100℃ / min)

[0313] (Thermal conductivity of storage container: ≥200W / m·K)

[0314] Quality Inspection Process

[0315] 1. Viability verification: After resuscitation, 100 μL of cell suspension was taken, stained with trypan blue (concentration 0.4%), and the proportion of viable cells was counted (standard: ≥90%).

[0316] 2. Label integrity: Confocal microscopy scanning quantum dot encoding (bit error rate ≤ 1×10⁻⁶) -6 )

[0317] 3. Gene stability: The AAVS1 site marker sequence was amplified by PCR, and the matching degree was verified by Sanger sequencing (≥99.9%).

[0318] Technological advantages

[0319] 1. Bioactive markers can dynamically reflect changes in an individual's physiological state.

[0320] 2. Cells retain their proliferative and differentiation capabilities after freezing and thawing.

[0321] 3. A dual-marker system (genetic + physical) ensures that information cannot be tampered with.

[0322] Four individual storage units can preserve the product for over 50 years.

[0323] Industrial applications

[0324] (1) Use of forensic identification for biological sample tracing

[0325] (2) Medical institutions establish personalized cell banks

[0326] (3) Long-term preservation of astronauts' biological information in the aerospace field

[0327] (4) Archiving of biometric information of important figures in cultural heritage protection Instruction manual with accompanying drawings Figure 1 Flowchart describing the main technical route for the creation and storage of cell marker imprints Figure 2 Flowchart description of fibroblast marker imprinting process.

Claims

1. A method for creating human cell marker imprints, characterized in that, Includes the following steps: (1) Isolate living cells with division potential from individual non-invasive tissues (skin, oral mucosa or hair follicles), preferably fibroblasts or mesenchymal stem cells; (2) Screening for highly active cell populations by flow cytometry or specific surface markers (such as CD90, CD105); (3) Expand the cells to the order of 10⁷ under three-dimensional suspension culture conditions using serum-free medium containing growth factors (FGF-2, EGF); (4) Use the CRISPR-dCas9 system to insert an identifier sequence containing an individual's unique ID and a timestamp at a genome-safe site (such as AAVS1); (5) A binary coding pattern that can be optically recognized is formed on the cell membrane surface using quantum dot fluorescent labeling technology; (6) The labeled cells are mixed with cryoprotectant (containing 8-12% DMSO, 15-25% fetal bovine serum and 0.3-0.8M trehalose), dispensed and then programmed to cool to -196℃ for long-term storage.

2. The method according to claim 1, characterized in that, The insertion of the gene marker sequence includes: Design DNA fragments ≤500bp, including a 32-bit hash code, an ISO 8601 timestamp, and a CRC-16 checksum; The dCas9-sgRNA complex and the marker sequence were co-transfected into cells by electroporation (1500V±50V, 10ms pulse). Flow cytometry sorts GFP-positive cells (transfection efficiency ≥70%, insertion success rate ≥85%).

3. The method according to claim 1, characterized in that, The quantum dot label includes: CdSe / ZnS quantum dots (emission wavelength 605 nm) conjugated with streptavidin using biotinylated antibodies (such as anti-CD29); Quantum dots are controlled by a microfluidic chip to form a 5×5 matrix encoding on the cell membrane, with an information density ≥2. 25 Combinations; The labeling stability meets the requirement that the signal retention rate is >90% after 12 months of liquid nitrogen storage.

4. The method according to claim 1, characterized in that, The cryopreservation step includes: The program cooling rate is 0.5-2℃ / min, and the final storage temperature is -150℃ to -196℃. Cell density 5×10 6 Up to 2×10 7 cells / mL, dispensed in volumes of 1-3 mL; Survival rate after resuscitation >95%, clone formation rate ≥70% of fresh cells.

5. The method according to any one of claims 1-4, characterized in that, It also includes a dual-channel information verification step: Binding gene layer identifier sequences to quantum dot encodings to blockchain (such as Hyperledger Fabric); Cross-validation using PCR sequencing and fluorescence imaging; a difference greater than 1 bit triggers an anti-counterfeiting alarm.

6. A storage system for human cell marker imprints, characterized in that, include: Low-temperature resistant biological capsules or aluminum storage tubes; Programmed cooling system (supports multi-segment cooling curves from 0.5-2℃ / min); Liquid nitrogen gas phase storage device (temperature monitoring accuracy ±3℃); A blockchain database used to record and verify genetic and physical layer marker information.

7. The system according to claim 6, characterized in that, The cryoprotectant further comprises 1-5% hydroxyethyl starch (HES) or antifreeze protein CP30 (1 ± 0.1 mg / mL).

8. A human cell marker imprint prepared by the method according to any one of claims 1-5, characterized in that: Chimeric unique identifier sequence at the AAVS1 site in the cell genome; The cell membrane surface has a quantum dot optical coding matrix; The resuscitation cell proliferation capacity was not significantly different from that of the primary cells (p>0.05).

9. The application of the cell marker imprinting described in claim 8 in individual identification, regenerative medicine, or biological sample tracing.

10. A method for monitoring cell viability, used for quality control of the marker imprints described in claims 1-5, characterized in that, include: Trypan blue staining for initial screening (viability ≥ 90%); Flow cytometry was used to monitor the apoptosis rate during the expansion phase (≤5%). ATP bioluminescence assay was used to detect cell viability after resuscitation (≥80% of fresh cells). Annual clone formation experiments verify long-term storage stability (clone formation rate ≥70%). The point to be protected is that the achievable effects of this patent cannot be simulated by dividing and applying the various functions of this patent in a separate manner. The embodiments of this invention are not limited to the above examples. The examples and patent descriptions are merely illustrative of the principles of this invention. Various changes and modifications can be made to this invention, and all such changes and modifications fall within the scope of the invention as claimed. The scope of protection of this invention is defined by the appended claims and their equivalents. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of this invention should be considered equivalent substitutions and are included within the scope of protection of this invention. The specific embodiments of the compound formulation of this invention are not exhaustive, and any modifications made by those skilled in the art without inventive effort are within the scope of protection of this invention.

Images